GlassScriptPhysician profile
Jacqueline Velez
NPI 1659935252
$6,842.49
in general payments reported to CMS, 2019-2025
42 companies · $797 in 2025
The $797 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $1,852 · 2023: $1,906 · 2024: $1,644 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,331 · Consulting Fee: $17.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,330.53 |
| Consulting Fee | $17.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $833.19 | 2021-2025 | Farxiga, Breztri, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $831.36 | 2021-2025 | Jardiance |
| Abbvie INC. | $784.22 | 2022-2025 | |
| Novo Nordisk INC | $634.15 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $578.77 | 2021-2024 | Xarelto |
| Pfizer INC. | $284.19 | 2022-2024 | |
| Amgen INC. | $279.72 | 2021-2025 | Repatha, Otezla |
| Lilly USA, LLC | $261.39 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $258.60 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $233.51 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $161.81 | 2021-2024 | Linzess |
| Exact Sciences Corporation | $159.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $133.99 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Redhill Biopharma INC. | $124.37 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $118.20 | 2022-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.